An international team of researchers has developed a novel fluorescent nanosensor powered by carbon nanotubes that is capable of rapidly detecting an emerging biomarker linked to gut health and disease. This important development could eventually lead to faster and more accessible gut-health testing.
Indole-3-propionic acid (IPA) is a metabolite produced by gut bacteria during the breakdown of dietary tryptophan, an essential amino acid. It plays an important role in regulating inflammation and oxidative stress and has been associated with conditions such as inflammatory bowel disease (IBD), Type 2 diabetes, and liver disease. Current detection methods rely on traditional mass spectrometry-based techniques, which are costly and time-consuming, making them impractical for routine screening or point-of-care use.
The new platform addresses a longstanding gap in gut metabolite sensing. Using a fluorescence-based approach, the sensor produces a rapid optical readout within minutes, offering a significantly faster and more accessible alternative to conventional analytical techniques. It demonstrates high selectivity, distinguishing IPA from closely related metabolites commonly found in the gut, enabling accurate detection even in complex biological environments such as blood serum.
“This is the first time we are able to directly and rapidly measure IPA levels in biological samples using an optical nanosensor,” says co-first author Mervin Ang, assistant professor at the National Institute of Education (NIE) within Nanyang Technological University in Singapore. “This novel approach, which moves away from traditional mass spectrometry, can pave the way towards faster and more accessible ways of monitoring gut health in real-world settings.”
The latest breakthrough is described in the research team’s open-access paper, "Fluorescent Nanosensor for Indole-3-Propionic Acid Detection in Gut Health Monitoring," in the journal Advanced Healthcare Materials. The work was led by researchers at NIE, MIT, and SMART, in collaboration with clinicians from the National University Hospital (NUH) and Yong Loo Lin School of Medicine within the National University of Singapore (NUS Medicine).
The new nanosensor builds on SMART DiSTAP’s research into nano and optical sensor technologies. Originally developed to monitor plant health, the technology has now been adapted for human health applications by redesigning the nano- and optical-sensing platform to detect IPA.
A key innovation of the technology is its dual-mode sensing capability. The nanosensor operates in both a visible fluorescence mode, enabling rapid, low-cost, high-throughput screening of biological samples; and a near-infrared mode, with wavelengths that can penetrate deeper into tissues. This flexibility allows the platform to be utilized in various environments, from laboratory tests to hospital bedside use, and wearable devices for real-time health monitoring.
To evaluate its clinical relevance, the research team collaborated with NUH clinicians to test the nanosensor on 125 human plasma samples. The study revealed significant differences in IPA levels between healthy individuals and patients with inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.
Beyond the laboratory, this research could pave the way for faster and more accessible gut health testing. Instead of relying on complex and time-intensive laboratory methods, the new nanosensor could enable rapid screening in clinics, or even portable or home-based testing, helping to detect gut diseases earlier and monitor treatment progress more easily.
Blogger's Review: This novel fluorescent nanosensor represents a significant breakthrough in the field of gut health detection. Its rapid and cost-effective nature could open up new possibilities for clinical applications, particularly in personalized medicine and remote monitoring. Future research should continue to explore the multifunctionality and portability of the sensor to achieve broader applications.